Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.

Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT.

Oncologist. 2011;16(6):772-82. doi: 10.1634/theoncologist.2010-0378. Epub 2011 May 31.

2.

Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs.

Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A Jr, Ueno NT, Buchholz TA.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1381-6. doi: 10.1016/j.ijrobp.2011.10.040. Epub 2012 Jan 26.

PMID:
22284689
3.

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.

Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP.

Cancer. 2009 Nov 1;115(21):5038-47. doi: 10.1002/cncr.24534.

4.

18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.

Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espié M.

J Nucl Med. 2013 Jan;54(1):5-11. doi: 10.2967/jnumed.112.106864. Epub 2012 Dec 4.

5.

¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37. doi: 10.1007/s00259-013-2595-4. Epub 2013 Nov 7.

PMID:
24196916
6.

Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G, Heusner TA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):852-63. doi: 10.1007/s00259-012-2077-0. Epub 2012 Mar 6.

PMID:
22392069
7.

Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.

Ng SP, David S, Alamgeer M, Ganju V.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):111-7. doi: 10.1016/j.ijrobp.2015.05.012. Epub 2015 May 15.

PMID:
26279029
8.

Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, Dose-Schwarz J.

Ann Oncol. 2008 Jul;19(7):1249-54. doi: 10.1093/annonc/mdn057. Epub 2008 Mar 19.

PMID:
18356138
9.

Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, Weber WA, Ulaner GA.

J Nucl Med. 2014 Oct;55(10):1578-83. doi: 10.2967/jnumed.114.143297. Epub 2014 Sep 11.

10.

FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.

Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT.

Oncologist. 2011;16(8):1111-9. doi: 10.1634/theoncologist.2011-0089. Epub 2011 Jul 17.

11.

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.

J Clin Oncol. 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18.

PMID:
19451443
12.

Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer.

Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Singh G.

Nucl Med Commun. 2013 Jun;34(6):557-61. doi: 10.1097/MNM.0b013e328360d910.

PMID:
23549551
13.

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.

Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, Fontanillas M, Pons F.

J Clin Oncol. 2008 Oct 10;26(29):4746-51. doi: 10.1200/JCO.2008.17.1496. Epub 2008 Aug 11.

PMID:
18695254
14.

Evaluation of a Case of Inflammatory Breast Cancer with 18F-FDG PET/CT.

Al-Faham Z, Al-Katib S, Jaiyesimi I, Bhavnagri S.

J Nucl Med Technol. 2015 Dec;43(4):289-91. doi: 10.2967/jnmt.114.148494. Epub 2015 Nov 19.

15.

Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT.

Breast Cancer Res Treat. 2015 Jul;152(2):407-16. doi: 10.1007/s10549-015-3436-x. Epub 2015 May 29. Erratum in: Breast Cancer Res Treat. 2015 Jul;152(2):417.

16.

The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.

Mittal BR, Manohar K, Kashyap R, Bhattacharya A, Singh B, Singh G.

Hell J Nucl Med. 2011 May-Aug;14(2):135-9.

PMID:
21761015
17.

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espié M.

J Natl Cancer Inst. 2012 Dec 19;104(24):1879-87. doi: 10.1093/jnci/djs451. Epub 2012 Dec 12.

18.

(18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?

Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J, Wasgindt S, Suetterlin M, Schoenberg SO, Sutton EJ, Wasser K.

Eur Radiol. 2015 Aug;25(8):2460-9. doi: 10.1007/s00330-015-3630-6. Epub 2015 Feb 15.

PMID:
25680729
19.

18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.

Baslaim MM, Bakheet SM, Bakheet R, Ezzat A, El-Foudeh M, Tulbah A.

World J Surg. 2003 Oct;27(10):1099-104. Epub 2003 Aug 18.

PMID:
12917770
20.

Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.

Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, Siegel C, Cao D, Gao F, Siegel BA.

J Clin Oncol. 2009 Sep 10;27(26):4314-20. doi: 10.1200/JCO.2008.20.6722. Epub 2009 Aug 3.

Supplemental Content

Support Center